This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Sangamo Biosciences, Inc.
Drug Names(s): AAV-NTN, Adeno-Associated Virus (AAV2)-Neurturin (NTN)
Description: CERE-120 uses an AAV2-based vector to deliver the gene for neurturin, a nervous system growth factor.
Deal Structure: Ceregene obtained exclusive worldwide rights to Neurturin through a licensing agreement with Washington University in St. Louis, MO.
Ceregene and Genzyme
In June 2007, Ceregene and Genzyme entered into a partnership for the development and commercialization of CERE-120 for the treatment of Parkinsons disease. Under the terms of the agreement, Genzyme will pay Ceregene a $25 million up-front payment in exchange for certain partnership-related expenses. Ceregene will also be entitled to development-related milestone payments of up to $125 million and 50 percent reimbursement of the worldwide Phase 3 development costs. Genzyme will gain marketing rights in all markets outside of the US and Canada, and Genzyme will pay Ceregene tiered royalties based on sales in markets where it has rights. Ceregene will retain exclusive rights to CERE-120 in the US and Canada.
Genzyme and Sanofi
In October 2010, Sanofi-aventis announced it has commenced a tender offer for all...See full deal structure in Biomedtracker
Pink Sheet Weekly Trademark Review Sept. 15, 2015
Additional information available to subscribers only: